Higher concentration insulins: an overview of clinical considerations
- PMID:28475455
- DOI: 10.1080/00325481.2017.1325311
Higher concentration insulins: an overview of clinical considerations
Abstract
Three higher concentration insulin products (insulin lispro 200 units/mL, insulin degludec 200 units/mL, and insulin glargine 300 units/mL) received US Food and Drug Administration (FDA) approval in 2015. Although human regular insulin 500 units/mL (U-500) was approved in 1997, a pen and dedicated U-500 syringe became available in 2016. These products offer more treatment options for the increasing numbers of patients requiring insulin to achieve and maintain glycemic targets. Higher concentration insulins have some unique safety and efficacy considerations. Important considerations when transitioning patients from the 100 unit/mL concentration (U-100) to the higher concentration include bioequivalence, pen dose increments, and pen appearance. Bioequivalent insulins have similar pharmacokinetic properties and no dose adjustments are expected when transitioning from the U-100 to the higher concentration. In contrast, higher concentration insulins with different pharmacokinetic and pharmacodynamic properties compared with the U-100 formulation may require dose adjustments. In order to provide safe and effective therapy to patients with higher daily insulin dose requirements, it is important for healthcare professionals to become very familiar with the characteristics of and differences between each of the higher concentration insulins. This paper highlights differences between the U-100 and higher concentration insulins and focuses on practical aspects of use.
Keywords: Bioequivalence; higher concentration insulin; insulin; insulin pen; type 2 diabetes.
Similar articles
- Concentrated insulins in current clinical practice.Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T.Schloot NC, et al.Diabetes Res Clin Pract. 2019 Feb;148:93-101. doi: 10.1016/j.diabres.2018.12.007. Epub 2018 Dec 21.Diabetes Res Clin Pract. 2019.PMID:30583034Review.
- The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?Maiorino MI, Petrizzo M, Capuano A, Giugliano D, Esposito K.Maiorino MI, et al.Expert Opin Biol Ther. 2014 Jun;14(6):799-808. doi: 10.1517/14712598.2014.895812. Epub 2014 Mar 27.Expert Opin Biol Ther. 2014.PMID:24673155Review.
- Understanding concentrated insulins: a systematic review of randomized controlled trials.Ovalle F, Segal AR, Anderson JE, Cohen MR, Morwick TM, Jackson JA.Ovalle F, et al.Curr Med Res Opin. 2018 Jun;34(6):1029-1043. doi: 10.1080/03007995.2017.1409426. Epub 2018 Jan 10.Curr Med Res Opin. 2018.PMID:29166786
- Concentrated insulins: History and critical reappraisal.Heinemann L, Beals JM, Malone J, Anderson J, Jacobson JG, Sinha V, Corrigan SM.Heinemann L, et al.J Diabetes. 2019 Apr;11(4):292-300. doi: 10.1111/1753-0407.12861. Epub 2018 Nov 13.J Diabetes. 2019.PMID:30264527Review.
- Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.Gallegos Aragon K, Elmaoued AA, Pham NT, Conklin JR, Ray GM.Gallegos Aragon K, et al.Cardiol Rev. 2019 Sep/Oct;27(5):260-266. doi: 10.1097/CRD.0000000000000266.Cardiol Rev. 2019.PMID:31393288Review.
Cited by
- Clinical Challenges With Concentrated Insulins: Setting the Record Straight.Brusko CSA, Taylor AD, Jackson JA, Bunck MC.Brusko CSA, et al.Diabetes Spectr. 2017 Nov;30(4):229-232. doi: 10.2337/ds17-0008.Diabetes Spectr. 2017.PMID:29151710Free PMC article.No abstract available.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical